Bank of New York Mellon
IMCR icon

Bank of New York Mellon’s Immunocore IMCR Stock Holding History

Bank of New York Mellon’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,896
Closed -$504K – 4543
2021
Q2 		$504K Buy
+12,896
New +$498K ﹤0.01% 3769

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Bank of New York Mellon's IMCR Position: Q3 2021 in Review

Bank of New York Mellon sold out of Immunocore (IMCR) in Q3 2021, closing a stake of 12,896 shares — an estimated $504K sold.

Bank of New York Mellon first reported a position in IMCR in Q2 2021 and held it in 1 quarter. The position peaked at $504K in Q2 2021. 47 funds tracked by Wall St. Rank hold IMCR as of Q3 2021.

  • Bank of New York Mellon reported no remaining Immunocore position as of Q3 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 12,896 Immunocore shares in Q3 2021, an estimated $504K.
  • Bank of New York Mellon first reported a position in Immunocore in Q2 2021 and held it in 1 quarter.
  • Bank of New York Mellon's Immunocore position peaked at $504K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Immunocore as of Q3 2021.

Based on Bank of New York Mellon's 13F filing for Q3 2021, filed 12 Nov 2021.